Siren Biotechnology

Home
United States
San Francisco, CA
Siren Biotechnology

We are revolutionizing the future of cancer treatment with universal AAV immuno-gene therapy! Follow us: https://www.sirenbiotechnology.com

05/05/2026

Siren Biotechnology is headed to next week! Find us at the events below to learn more about our path to the clinic with , our lead AAV immuno for . See you in Boston!

04/27/2026

BIG moment for ! 🚨

We’re thrilled to share that our first peer-reviewed manuscript is now published in Molecular Therapy Oncology - and we’re heading to 2026 with even more data to share!

This publication showcases the foundation of our Universal AAV Immuno-Gene Therapy platform, including groundbreaking preclinical data in high-grade glioma, one of the toughest cancers with the greatest unmet need.

What we’re seeing:

🧬 Durable localized cytokine expression

🔥 Robust anti-tumor activity across multiple orthogonal human model systems

📉 Profound tumor regression + significantly increased survival

🎯 Tumor-localized immune activation

Huge thanks to our team and collaborators for supporting this work!

👉 Read the full press release here: https://sirenbiotechnology.com/siren-biotechnology-publishes-foundational-aav-immuno-gene-therapy-data-and-announces-presentations-at-asgct-2026/

👉 Access the open access manuscript here: [https://www.cell.com/molecular-therapy-family/oncology/fulltext/S2950-3299(26)00059-7](https://www.cell.com/molecular-therapy-family/oncology/fulltext/S2950-3299(26)00059-7)

Want more, like our IND large animal data? Come find us at !

04/08/2026

Join Siren Biotechnology's CEO and other industry leaders at the National Organization for Rare Disorders, Inc. (NORD) Scientific Symposium next week! We’ll be sharing ways to bring community members in as company stakeholders through community fundraising. Register here: https://nordscience.org/

03/23/2026

Big news for SRN-101 🚀 The FDA has cleared a second IND to launch a Phase 1 trial with SRN-101 in recurrent high-grade glioma. This investigator-initiated study, led by Dr. Nicholas Butowski at UCSF, marks an exciting step forward in expanding clinical evaluation of SRN-101. We’re proud to support the UCSF team as they advance this important work for patients in need.
Learn more: https://sirenbiotechnology.com/Siren-Biotechnology-Announces-FDA-Clearance-of-Investigator-Initiated-IND-to-Advance-Phase-1-Study-in-Recurrent-High-Grade-Glioma/

02/24/2026

On the heels of IND clearance for SRN-101, we are thrilled to announce another major milestone at Siren Biotechnology! 🚀

The FDA has granted Fast Track Designation to SRN-101, our lead Universal AAV Immuno-Gene Therapy candidate for recurrent high-grade glioma.

Fast Track status reinforces the urgency and potential impact of bringing this first-of-its-kind AAV-based immuno-gene therapy to patients facing one of the most devastating cancers.

Momentum is building, and we’re just getting started. 💥

02/05/2026

Siren Biotechnology is heading to Phacilitate next week. Our Founder & CEO, Nicole K. Paulk, PhD, and our SVP of Vector Development, Nathalie Clement, look forward to meeting with partners, peers, and fellow leaders pushing the field forward. If you’ll be in San Diego, we’d love to see you!

01/28/2026

A big day of celebration here ! 🎉 We’re thrilled to share that the FDA has cleared our first IND for SRN-101, enabling our Phase I/II trial of what we believe is the first for any clinically.

This milestone marks a major step forward in bringing SRN-101 to patients with recurrent high-grade glioma. Huge congratulations to our incredible team, advisors, and partners who helped make this moment possible!

01/07/2026

It’s a busy start to 2026 at Siren Biotechnology! We’re excited to be out in full force at , , and . Come meet with us at:
📍 JPM Jan 12-15 | San Francisco, CA
📍 Advanced Therapies Feb 9-12 | San Diego, CA
📍 Biocom Feb 24-26 | La Jolla, CA
If you’ll be there too, let’s connect!

12/23/2025

Happy holidays from the Siren Biotechnology team!🎄Our key moments were submitting our first IND to the FDA (today!) and closing our first-ever community investment round. But these can’t overshadow all the other accomplishments our team had in 2025. In all, we counted:
⚡ 8 new cancer indications tested
💸 1,529 new investors
✍️ First IND filed
🧠 3 new SAB members
🧪 10 formal assay qualifications
🏅 3 big awards received
🧬 100+ new constructs screened
💪 1 cancer diagnosis AND recovery!
💼 7 conferences attended
🐣 1 new baby
📆 50 weekly syncs and 26 lab meetings
🥹 1 proud team with ♾️ accomplishments…make that ♾️ + 1! 💛
Stay tuned for our 2026 tally…

10/20/2025

Wow — what a way to close out our first-ever community round! 🎉

We’re incredibly grateful to the 1,600+ investors who joined our mission and helped us raise over $4.2 million to support the next generation of cancer gene therapy.

This round wasn’t just about funding. It was about opening the doors to patients, families, advocates, doctors and anyone who believes cancer care has to be faster, smarter, and more effective.

We’re honored to have you with us on this journey.

📝Check out our final campaign update on Wefunder: https://wefunder.com/siren.biotechnology/feed/208490-4-22-million-raised-1-626-investors-thank-you

Here’s to an exciting chapter ahead!

Address

San Francisco, CA

Website

http://www.sirenbiotechnology.com/

Alerts

Be the first to know and let us send you an email when Siren Biotechnology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your business to be the top-listed Engineering Company in San Francisco?